Canabinóides

Applications Labelled analogue of a cannabimimetic indole derivative that acts as both a cannabinoid receptor CB1 and CB2 agonist. References Huffman J.W. et al.: Bioorg. Med. Chem. Lett., 15, 4110 (2005); De Freitas, G.B.L. et al.: Eur. J. Med. Chem., 44, 2482 (2009); Tuccinardi, T. et al.: J. Med. Chem., 49, 984 (2006);

Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also

ML192 (CID1434953) is a selective GPR55 ligand antagonist.

Applications An N-1 alkyl indole cannabinoid receptor agonist. The N-1 alkyl chain length of cannabimimetic indoles influences CB1 and CB2 receptor binding. References D'Ambra, T., et al.: J. Med. Chem., 35, 124 (1992), Cheng, Y., et al.: Biochem. Pharmacol., 22, 3099 (1973), Pertwee, R., et al.: Eur. J. Pharmacol., 284, 241 (1995),

Applications (Z)-2-Nonen-1-ol is an intermediate in the synthesis of Falcarinol (F101100), a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. References Czepa, A., et al.: J. Agric. Food Chem., 52, 4508 (2004), Radulovic, N., et al.: Chem. Nat. Compds., 44, 390 (2008),

Oxygen-heterocyclic compound

Polyphenol

(±)-Cannabichromene is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the TRPA1.

Applications Labelled JWH-200 (M723765). An analgesic compound which acts as a partial agonist at both the CB1 and CB2 cannabinoid receptors. References Compton, D., et al.: J. Pharmacol. Exper. Ther., 263, 1118 (1992), Tetko, I., et al.: J. Med. Chem., 44, 2411 (2001), Huffman, J., et al.: Bioorg. Med. Chem., 11, 539 (2003),

Applications 3-Cysteinylacetaminophen-D5 (major), Trifluoroacetic Acid Salt is deuterium labeled 3-Cysteinylacetaminophen Trifluoroacetic Acid Salt (C994750), which is a metabolite of Acetaminophen (A161220), an analgesic and antipyretic agent used as a pain reliever to treat headache, muscle aches, and arthritis (1,2,3).Minimum isotopic incorporation d-3, no d-0 present. A representative lot has 64% isotopic incorporation at the 6-position, 89% at the 4-position. References (1) McGill, M. R. and Jaeschke, H. Pharm Res. 30, 2174 (2013)(2) Fairbrother, J.E., et al.: Anal. Profiles Drug Subs., 3, 1 (1974) (3) Hinson, J.A., et al.: Rev. Biochem. Toxicol., 2, 103 (1980)

rel-(1R,2S)-8-Bromo-1-(3-bromo-4-hydroxy-5-methoxyphenyl)-1,2-dihydro-7-hydroxy-N2,N3-bis[2-(4-hydroxyphenyl)ethyl]-6-methoxy-2,3-naphthalenedicarboxamide is a synthetic chemical compound, which is derived through targeted organic synthesis and structural optimization efforts. Its source lies in advanced laboratory methodologies designed to enhance specific pharmacological properties. The mode of action is expected to involve selective interaction with particular molecular targets, potentially modulating distinct pathways related to cellular function or signaling processes. This compound is currently under investigation for its potential applications in therapeutic settings, where it might offer novel approaches to modulating disease mechanisms. Specifically, its structure suggests possible utility in addressing oxidative stress, inflammatory pathways, or hormonal signaling, although detailed biological studies will be necessary to confirm these roles. Furthermore, its unique structure and functional groups could serve as a prototype for developing more refined analogs aimed at achieving greater efficacy and specificity in disease treatment regimens. Rigorous preclinical and clinical evaluations are essential to uncover its full utility and therapeutic potential within the scientific and medical communities.

NESS 0327 is a high selectivity antagonist of the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor.

SCH-336: potent, selective CB2 agonist (Ki=1.8 nM, EC50=2 nM), orally active, 100x CB2 vs. CB1 preference, reduces leukocyte migration and eosinophilia.